Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb drops Opcon-A comparative ad claims after Ciba NAD challenge.

This article was originally published in The Tan Sheet

Executive Summary

BAUSCH & LOMB DISCONTINUES CERTAIN OPCON-A EYE DROP ADS following a written agreement with Ciba Vision, which manufactures Vasocon-A eye drops. According to a recent case report issued by the National Advertising Division of the Council of Better Business Bureaus, Ciba took issue with print and television ads for Bausch & Lomb's Opcon-A that claimed that Opcon-A is "the only eye drop that relieves both redness and itching" and that "no other eye drop calms and clears your eyes like new Opcon-A." Ciba filed a complaint with NAD about the Bausch & Lomb claims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS084156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel